The company's Edison Platform uses advanced imaging and proprietary sensing technology to deliver personalized, tissue-specific treatments with precision and control. The platform uses the science of histotripsy and focused sound energy to generate pressures that liquify and completely destroy targeted tissues at sub-cellular levels. The non-invasive nature of the therapy allows physicians to continuously monitor the treatment and its effect in real-time, without the undesirable side effects of many of today's interventional and surgical modalities. HistoSonics is backed by venture capital and led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.